{"name":"Zensun Sci. & Tech. Co., Ltd.","slug":"zensun-sci-tech-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Recombinant human Neuregulin for injection","genericName":"Recombinant human Neuregulin for injection","slug":"recombinant-human-neuregulin-for-injection","indication":"Acute myocardial infarction","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Neucardin","genericName":"Neucardin","slug":"neucardin","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Recombinant human Neuregulin for injection","genericName":"Recombinant human Neuregulin for injection","slug":"recombinant-human-neuregulin-for-injection","phase":"phase_3","mechanism":"Recombinant human Neuregulin for injection is a growth factor that promotes cardiac repair and regeneration.","indications":["Acute myocardial infarction","Heart failure"],"catalyst":""},{"name":"Neucardin","genericName":"Neucardin","slug":"neucardin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPbjg4LTlRUFctbDhaMW5BMnJoQUZfenBCdVNSRENoLXQzZHpEYm45QnlnTHI4QnFNZXd0ZUhkdzNpTWQ3eFAydjZqcmxsYVg1SUpLN01wdmJZRjcxTEU3SWg0d3AtZGU3QVo0aVc5cnVUeHUtRmZLSDBYVk5JeVJtM1VYcUlDN3duWTNETE5HTjlpRGRlR0JYc2RETGNWQ09CMTdzTUhtNVBaQTliUjJUaQ?oc=5","date":"2013-05-27","type":"pipeline","source":"Asian Scientist Magazine","summary":"Zensun Announces Ph II Results For Neucardin™ Heart Failure Drug - Asian Scientist Magazine","headline":"Zensun Announces Ph II Results For Neucardin™ Heart Failure Drug","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}